跳至主要内容
临床试验/NCT01465295
NCT01465295已完成不适用

Prospective Trial to Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis

SpineForm LLC4 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2011年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6
试验地点
4
主要终点
Acute Safety: Incidence, relatedness (relationship to procedure and device), seriousness and severity of Adverse Events By Participant

研究概览

简要总结

The purpose of this clinical trial is to study a new method of treatment for patients who are diagnosed with idiopathic scoliosis and have abnormal and increasing curvature of the spine. The treatment consists of the surgical implantation of a new medical device called the "HemiBridge™ Clip". This medical implant device has never been used in humans. SpineForm, LLC, the developer of the HemiBridgeTM System has designed this scientific clinical trial, to evaluate the safety of the use of this device in humans. Information collected from patients treated with this new device shall be used to determine the initial safety of the new device.

The FDA has approved the use of the HemibridgeTM System for this research study in 6 (six) pediatric patients who have idiopathic scoliosis.

This procedure is intended to stop additional curvature of the spine by redirecting growth of the bones of the spine (vertebrae). To accomplish this, the patient undergoes a surgical procedure to securely attach small metal clips (HemiBridge™ Clips) to the outer side of each vertebra involved in the curvature. The HemiBridge™ Clip forms a "bridge" between each vertebra and is intended to hold the vertebrae in place to prevent the spine from curving any further.

详细描述

Significance Spinal deformity fusion treatment involves some of the most costly and invasive procedures in orthopaedics. The development of an effective treatment method to avoid fusion is needed. Many pediatric spine specialists concur that growth modulation displays compelling pre-clinical and clinical data that must be studied further. While bracing is the only non-operative modality with any evidence of effectiveness for idiopathic scoliosis, its level of effectiveness compared to observation or natural history remains inconclusive. Research has been published for over 50 years, yet conflicting literature reports both successes and failures. Most literature consists of retrospective reports of bracing experience, with little commonality relative to existing conditions at the time bracing is initiated, documentation of compliance and basis for judging success.

The U.S. Preventative Services Task Force (USPSTF) is an independent panel of private-sector experts in primary care and prevention. The Task Force was convened by the U.S. Public Health Service to systematically review the evidence of effectiveness of clinical preventive services. One of their charges was to evaluate the evidence supporting the practice of school screening for adolescent idiopathic scoliosis. After systematically reviewing the literature to date, their policy statement issues in 1992, and updated in 1996 states "...There is inadequate evidence to determine whether brace therapy limits the natural progression of the disease in a significant proportion of cases, as most studies suffer from selection bias, lack of internal control groups, inadequate follow-up, small sample sizes, and lack of health outcome measures."

There is no Level One evidence to support the practice of bracing, and clinicians are left with conflicting and questionable inferences regarding bracing effectiveness. Some clinicians believe the evidence favors a decrease in the rate of curve progression, and based on this assumption, over half the states in the U.S. have mandated school screening programs for the detection and early treatment of scoliosis. On the other hand, groups such as the USPSTF, its British and Canadian counterparts and many individual practitioners worldwide feel the evidence is inconclusive and are therefore ambivalent about brace treatment.

Due to the variability in published results on brace effectiveness, researchers in the United States and Canada have commenced a randomized multi-center trial of bracing versus no bracing to determine the effectiveness of brace wear in the treatment of idiopathic scoliosis (BRAIST Study). This study, which was initiated in 2007 in the United States, is being performed under the auspices of the US National Institutes of Health (NIH) and Canadian Institute of Health. In the Netherlands, a randomized multi-center study comparing bracing to observation is also underway.

While bracing treatment is non-invasive and preserves growth, motion and function of the spine, it does not correct the deformity. In addition, the brace pressure on the rib cage and the influence on the chest wall in a growing child create concerns. Some scoliosis patients wear a brace for as long as five years only to learn that brace treatment failed and then recommended to endure major fusion surgery and recovery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must meet all the criteria to be enrolled in this study:
  • Trial subject population will involve patients who are skeletally immature, who have a diagnosis of idiopathic scoliosis with a single main thoracic curve Cobb angle 25° to 40° and Lenke Type 1A or 1B.
  • Chronologic age:
  • Males ≥ 10 years
  • Females ≥ 10 years
  • Females pre-menarchal at screening examination
  • Bone age as confirmed by radiographs of left hand and wrist according to the "Atlas Matching" method of Greulich and Pyle:
  • Females: ≥ 8 years and 10 months not to exceed 13 years
  • Males: ≥ 10 years not to exceed 15 years
  • Skeletal immaturity (Risser grade 0 and the triradiate cartilage is open) as determined by standing, upright PA radiograph. If radiographic Risser grade results are indeterminate, the bone age from the Atlas Matching will prevail.
  • Main thoracic Cobb angle of 25° to 40° as determined from standing, upright PA radiographs where the end vertebra are between or including T3 and L1 without wearing a brace
  • Clinical diagnosis of idiopathic scoliosis with a single main thoracic curve as determined with measurement on standing posterior- anterior PA radiographs.
  • Defined as a single thoracic curve where either: central sacral vertical line (CSVL) passes between the pedicles of the apical lumbar vertebra; or the CSVL touches the lumbar apical body(ies) (Lenke Type 1A or 1B, respectively)
  • Achievable anatomical fit as determined by calibrated standing PA film:
  • Disc height not exceeding 10 mm at each spinal level to be instrumented relative to location of the probable implant and
  • Minimum central vertebral height that will accept the selected HemiBridge™ Clip size at all levels planned for implants
  • Physical and mental ability to undergo surgery with single lung ventilation
  • Written informed assent from the patient
  • Written informed consent from parent and/or legal guardian and authorization to use protected health information (by Sponsor, third party core lab and/or clinical evaluation committee)

排除标准

  • Patients who meet any of the exclusion criteria will not be enrolled.
  • Non-idiopathic scoliosis
  • Males and females chronological age < 10 years
  • Triradiate cartilage is closed as determined on the standing PA radiograph at baseline screening
  • Any curve type that does not meet definition of Lenke 1A or 1B
  • Any main thoracic deformity that measures < 25° or > 40° Cobb angle
  • Any main thoracic deformity that includes vertebral levels including and cranial to T2
  • Any main thoracic deformity that includes vertebral levels including and caudal to L2
  • Prior thoracotomy, thoracostomy or any spine surgery
  • T3-T12 kyphosis > 40° (T4 or T5-T12 if visualization impaired at T3)
  • Known history or existing malignancy, or any systemic or local infection
  • Spinal cord abnormalities that require treatment
  • Presence of neurological deficit (motor grades 0-4, sensory grades 0-1, reflexes grade 0 or 5 or asymmetry of deep tendon reflexes > 2 from right to left)
  • Insulin-dependent diabetes
  • Severe asthma
  • Reduced pulmonary function, defined as < 60% of predicted value (Forced expiratory volume in one second [FEV1] divided by forced vital capacity [FVC]) or Subject has moderately severe or worse ventilatory limitation defined as < 60% of predicted value of the forced vital capacity [FVC] for age, race, sex and height (with height determined by arm span in patients with scoliosis and reference equations derived from the data of Wang et al 199329.)
  • Cardiopulmonary or other systemic disease
  • Bleeding disorder(s)
  • Documented HIV or hepatitis infection
  • Family history of neurofibromatosis or Marfan's syndrome
  • Medical contraindication to anesthesia
  • Suspected or known allergy to titanium
  • Not available for interval visits and long term follow-up exams

研究组 & 干预措施

HemiBridge

Experimental

Patients meeting eligibility criteria will be treated with the HemiBridge System.

干预措施: Mechanical hemiepiphysiodesis using the HemiBridge System (Device)

结局指标

主要结局

Acute Safety: Incidence, relatedness (relationship to procedure and device), seriousness and severity of Adverse Events By Participant

时间窗: 1 month post-operative

Incidence, relatedness (relationship to procedure and device), seriousness and severity of Adverse Events By Participant

次要结局

未报告次要终点

研究者

发起方
SpineForm LLC
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验